Table 2 |
||||
|
Estimated proportion of patients with relapse of upper gastrointestinal symptoms |
||||
| NASA2 study |
p value versus placebo |
SPACE2 study |
p value versus placebo |
|
|
|
||||
| Placebo |
38.2% |
- |
39.8% |
- |
| Esomeprazole 20 mg |
28.3% |
0.04 |
30.7% |
0.07 |
| Esomeprazole 40 mg |
24.3% |
0.004 |
28.4% |
0.05 |
|
|
||||
|
Kaplan-Meier life-table estimates of proportion of patients with relapse of pain, discomfort, or burning in the upper abdomen throughout 6 months of treatment with esomeprazole 20 mg, esomeprazole 40 mg, or placebo and log-rank comparisons for the individual studies. NASA, Nexium Anti-inflammatory Symptom Amelioration; SPACE, Symptom Prevention by Acid Control with Esomeprazole. |
||||
|
Hawkey et al. Arthritis Research & Therapy 2007 9:R17 doi:10.1186/ar2124 |
||||
